<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Stroke</journal-id><journal-id journal-id-type="iso-abbrev">Int J Stroke</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1747-4949</journal-id><journal-id journal-id-type="publisher-id">IJS</journal-id><journal-title-group><journal-title>International Journal of Stroke</journal-title></journal-title-group><issn pub-type="ppub">1747-4930</issn><issn pub-type="epub">1747-4949</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5324659</article-id><article-id pub-id-type="doi">10.1111/ijs.12602</article-id><article-id pub-id-type="publisher-id">IJS12602</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group><subj-group subj-group-type="overline"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Statistical analysis plan for evaluating low‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED) </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="left-running-head">C. <styled-content style="fixed-case">S</styled-content>. <styled-content style="fixed-case">A</styled-content>nderson <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="ijs12602-cr-0001" contrib-type="author" corresp="yes"><name><surname>Anderson</surname><given-names>Craig S.</given-names></name><xref ref-type="aff" rid="ijs12602-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijs12602-cr-0002" contrib-type="author"><name><surname>Woodward</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="ijs12602-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijs12602-cr-0003" contrib-type="author"><name><surname>Arima</surname><given-names>Hisatomi</given-names></name><xref ref-type="aff" rid="ijs12602-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ijs12602-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ijs12602-cr-0004" contrib-type="author"><name><surname>Chen</surname><given-names>Xiaoying</given-names></name><xref ref-type="aff" rid="ijs12602-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijs12602-cr-0005" contrib-type="author"><name><surname>Lindley</surname><given-names>Richard I.</given-names></name><xref ref-type="aff" rid="ijs12602-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijs12602-cr-0006" contrib-type="author"><name><surname>Wang</surname><given-names>Xia</given-names></name><xref ref-type="aff" rid="ijs12602-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijs12602-cr-0007" contrib-type="author"><name><surname>Chalmers</surname><given-names>John</given-names></name><xref ref-type="aff" rid="ijs12602-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ijs12602-cr-0008" contrib-type="author"><collab collab-type="authors">ENCHANTED Investigators</collab></contrib></contrib-group><aff id="ijs12602-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">The George Institute for Global Health</named-content><institution>Royal Prince Alfred Hospital and University of Sydney</institution><named-content content-type="city">Sydney</named-content><named-content content-type="country-part">NSW</named-content><country country="AU">Australia</country></aff><aff id="ijs12602-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Centre for Epidemiologic Research in Asia</named-content><named-content content-type="organisation-division">Shiga University of Medical Sciences</named-content><institution>Shiga University</institution><named-content content-type="city">Shiga</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence: Craig S. Anderson, Neurological and Mental Health Division, The George Institute for Global Health, Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW 2050, Australia.<break/>
E‐mail: <email>canderson@georgeinstitute.org.au</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><volume>10</volume><issue>8</issue><issue-id pub-id-type="doi">10.1111/ijs.2015.10.issue-8</issue-id><fpage>1313</fpage><lpage>1315</lpage><history><date date-type="received"><day>28</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2015 The Authors. International Journal of Stroke published by John Wiley &amp; Sons Ltd on behalf of World Stroke Organization.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:IJS-10-1313.pdf"/><abstract><sec id="ijs12602-sec-0001"><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>The ENhanced Control of Hypertension And Thrombolysis strokE stuDy trial is a 2 × 2 quasi‐factorial active‐comparison, prospective, randomized, open, blinded endpoint clinical trial that is evaluating in thrombolysis‐eligible acute ischemic stroke patients whether: (1) low‐dose (0·6 mg/kg body weight) intravenous alteplase has noninferior efficacy and lower risk of symptomatic intracerebral hemorrhage compared with standard‐dose (0·9 mg/kg body weight) intravenous alteplase; and (2) early intensive blood pressure lowering (systolic target 130–140 mmHg) has superior efficacy and lower risk of any intracerebral hemorrhage compared with guideline‐recommended blood pressure control (systolic target &lt;180 mmHg). </plain></SENT>
</text></SecTag></p></sec><sec id="ijs12602-sec-0002"><title><text><SENT sid="3" pm="."><plain>Objective </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>To outline in detail the predetermined statistical analysis plan for the ‘alteplase dose arm’ of the study. </plain></SENT>
</text></SecTag></p></sec><sec id="ijs12602-sec-0003"><title><text><SENT sid="5" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>All data collected by participating researchers will be reviewed and formally assessed. </plain></SENT>
<SENT sid="7" pm="."><plain>Information pertaining to the baseline characteristics of patients, their process of care, and the delivery of treatments will be classified, and for each item, appropriate descriptive statistical analyses are planned with appropriate comparisons made between randomized groups. </plain></SENT>
<SENT sid="8" pm="."><plain>For the trial outcomes, the most appropriate statistical comparisons to be made between groups are planned and described. </plain></SENT>
</text></SecTag></p></sec><sec id="ijs12602-sec-0004"><title><text><SENT sid="9" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="10" pm="."><plain>A statistical analysis plan was developed for the results of the alteplase dose arm of the study that is transparent, available to the public, verifiable, and predetermined before completion of data collection. </plain></SENT>
</text></SecTag></p></sec><sec id="ijs12602-sec-0005"><title><text><SENT sid="11" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>We have developed a predetermined statistical analysis plan for the ENhanced Control of Hypertension And Thrombolysis strokE stuDy alteplase dose arm which is to be followed to avoid analysis bias arising from prior knowledge of the study findings. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author-generated"><kwd id="ijs12602-kwd-0001">acute</kwd><kwd id="ijs12602-kwd-0002">alteplase</kwd><kwd id="ijs12602-kwd-0003">clinical trials</kwd><kwd id="ijs12602-kwd-0004">statistical analysis plan</kwd><kwd id="ijs12602-kwd-0005">stroke</kwd><kwd id="ijs12602-kwd-0006">thrombolysis</kwd></kwd-group></SecTag><funding-group><award-group><funding-source>National Health and Medical Research Council (NHMRC)</funding-source><award-id>1020462</award-id></award-group></funding-group><funding-group><award-group><funding-source>Stroke Association of the United Kingdom</funding-source><award-id>TSA 2012/01</award-id></award-group></funding-group><funding-group><award-group><funding-source>National Council for Scientific and Technological Development of Brazil</funding-source><award-id>467322/2014‐7</award-id></award-group></funding-group><funding-group><award-group><funding-source>Ministry for Health, Welfare, and Family Affairs of the Republic of Korea</funding-source><award-id>HI14C1985</award-id></award-group></funding-group><counts><page-count count="3"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>ijs12602</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.7 mode:remove_FC converted:24.02.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="ijs12602-note-0001"><p><text><SENT sid="13" pm="."><plain>Conflict of interest: None declared. </plain></SENT>
</text></p></fn><fn id="ijs12602-note-0002"><p><text><SENT sid="14" pm="."><plain>Trial registration: <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01422616), ISRCTN Register (ISRCTN82387104), and Australian New Zealand Clinical Trial Registry (ACTRN12611000236998). </plain></SENT>
</text></p></fn><fn id="ijs12602-note-0003"><p><text><SENT sid="15" pm="."><plain>Funding: The National Health and Medical Research Council (NHMRC) of Australia (Project Grant number 1020462), the Stroke Association of the United Kingdom (Reference TSA 2012/01), the National Council for Scientific and Technological Development of Brazil (CNPq grant number 467322/2014‐7), and the Ministry for Health, Welfare, and Family Affairs of the Republic of Korea (HI14C1985). </plain></SENT>
</text></p></fn></fn-group></notes></front><body><p><text><SENT sid="16" pm="."><plain>Alteplase is the recombinant form of the naturally occurring tissue plasminogen activator (t‐PA) that is produced by endothelial and other vascular cells. </plain></SENT>
<SENT sid="17" pm="."><plain>It was the first recombinant tissue plasminogen activator (rt‐PA) to be licensed for the management of various thromboembolic diseases including acute myocardial infarction in 1987, massive pulmonary embolism in 1990, and acute ischemic stroke (AIS) in 1996. </plain></SENT>
<SENT sid="18" pm="."><plain>The basis of the latter license was the pivotal National Institutes of Neurological Diseases and Stroke (NINDS) trial 1, where use of intravenous (iv) alteplase at a dose of 0·9 mg/kg body weight (10% as bolus, 90% as a one‐hour infusion; maximum dose 90 mg) within three‐hours of the onset of symptoms was shown to improve outcome in carefully selected patients with AIS. </plain></SENT>
<SENT sid="19" pm="."><plain>Subsequent systematic reviews of all the randomized trials of alteplase involving nearly 7000 patients with AIS have shown the evidence is strong for alteplase to provide an overall net benefit within 4·5 h of onset, despite increased (2–7%) risks of symptomatic intracranial hemorrhage (sICH) and early death. </plain></SENT>
<SENT sid="20" pm="."><plain>Moreover, the efficacy of the treatment is critically time dependent; earlier use of alteplase provides greater proportional benefit 2, 3. </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>Compared with the cardiology literature, it is surprising that there has been so little research into the optimal dose of alteplase in AIS, or of the importance of ancillary treatments such as early intensive control of blood pressure (BP), to further improve outcome of such patients. </plain></SENT>
<SENT sid="22" pm="."><plain>The standard 0·9 mg/kg dose of alteplase was chosen for the NINDS trial on the basis of small pilot dose escalation studies which showed that higher doses were related to the risk of sICH, but no clear correlation was found between treatment and early neurological improvement 4, 5, 6. </plain></SENT>
<SENT sid="23" pm="."><plain>At about the same time, small double‐blind randomized controlled trials of duteplase (which is similar to rtPA) in patients with AIS in Japan showed that 20 mega‐international units (MIUs) of duteplase (equal to 0·33 MIU/kg or 0·6 mg/kg of rtPA) was not only superior to placebo and comparable with 30 MIU on both angiographic recanalization and clinical improvement, but also that massive ICH was more frequent with 30 MIU of duteplase 7, 8. </plain></SENT>
<SENT sid="24" pm="."><plain>Low‐dose alteplase (0·6 mg/kg) was subsequently approved in Japan after the Japan Alteplase Clinical Trial 9, an open nonrandomized evaluation of patients within three‐hours of AIS, showed equivalent clinical outcomes and reduced risk of sICH when compared with trials of the standard 0·9 mg/kg dose of alteplase. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>Uncertainty over the most efficacious dose and safety of alteplase has resulted in variations in dose regimes and proposed therapeutic response and risks of sICH in the treatment of AIS patients in Asia 10. </plain></SENT>
<SENT sid="26" pm="."><plain>In many countries outside of Japan, low‐dose alteplase has become an attractive ‘low‐cost’ or ‘safer’ option for those who cannot afford the full dose or are elderly. </plain></SENT>
<SENT sid="27" pm="."><plain>The high cost of alteplase (∼US$2000 per 2 × 50 mg vials for the 0·9 mg/kg dose) is a major out‐of‐pocket expense for many people in fee‐for‐service health care systems of low‐middle income countries (and even in deprived sections of populations in high income countries) in many parts of the world 11. </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>There is strong rationale to expect the effects of alteplase to vary across different AIS patient groups and for interaction between dose and hemostatic and cerebrovascular factors. </plain></SENT>
<SENT sid="29" pm="."><plain>In particular, Asians are more likely to have AIS with lower ‘clot volume’ due to the greater frequency of small vessel or ‘lacunar’ forms of AIS as compared with more large vessel and cardio‐embolic strokes in non‐Asians 12. </plain></SENT>
<SENT sid="30" pm="."><plain>Standard‐dose alteplase may be better in situations of larger proximal vessel clots, while low‐dose alteplase may be better and safer (i.e. less sICH) for small platelet‐rich clots in more distal or smaller perforating cerebral vessels causing lacunar strokes. </plain></SENT>
<SENT sid="31" pm="."><plain>Moreover, the Get‐with‐the‐Guidelines stroke quality assurance registry in the United States has shown that Asian AIS patients have an increased risk of sICH with given standard‐dose alteplase 13. </plain></SENT>
<SENT sid="32" pm="."><plain>As highlighted in a Cochrane review where no clear differences were seen in outcomes through indirect comparisons of different dosages of thrombolytic agents 14, there will be continued uncertainty over the relative benefits and risks of low‐ vs. standard‐dose alteplase in the absence of direct head‐to‐head comparative studies. </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>As the largest randomized evaluation of alteplase in AIS, the ENhanced Control of Hypertension And Thrombolysis strokE stuDy (ENCHANTED) has been designed as a comparative effectiveness trial to resolve uncertainty over the most efficacious dose of alteplase as well as the most appropriate level of control of elevated BP in the context of AIS. </plain></SENT>
<SENT sid="34" pm="."><plain>Planning for the study began in 2010 after completion of the pilot phase Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT1) 15 showed potential benefits of early intensive BP lowering in patients with acute ICH. </plain></SENT>
<SENT sid="35" pm="."><plain>As low‐dose alteplase and early intensive BP lowering both have the potential to make thrombolytic treatment more efficacious, safer, and affordable in patients with AIS around the world, it was important that ENCHANTED had pragmatic features to allow its efficient conduct in the context of routine clinical practice, and for the results to be widely generalizable. </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>The study protocol for ENCHANTED has been outlined elsewhere 16. </plain></SENT>
<SENT sid="37" pm="."><plain>In brief, the study was designed as a quasi‐factorial randomized controlled trial involving two linked comparative treatment arms – ‘alteplase dose’ and ‘BP control’ – with overlapping eligibility criteria. </plain></SENT>
<SENT sid="38" pm="."><plain>As well as providing flexibility over patient recruitment into one or both treatment arms according to clinician uncertainty and available resources, the study design allows for the two treatment arms to be evaluated separately. </plain></SENT>
<SENT sid="39" pm="."><plain>The randomization, data collection, follow‐up, and monitoring systems were modeled on the main phase INTERACT2 study 17, where a global network was established to provide a reliable estimate of a clinically worthwhile beneficial effect of a treatment strategy that would influence clinical practice. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>Herein we describe the statistical analysis plan (SAP) for the ENCHANTED ‘alteplase dose’ arm, where patient recruitment has been more rapid and the required sample size will be achieved sooner than for the BP control arm. </plain></SENT>
<SENT sid="41" pm="."><plain>This SAP was completed prior to completion of the data collection, and is what investigators will adhere to in analyzing the results of the study pertaining to the dose of alteplase in AIS. </plain></SENT>
<SENT sid="42" pm="."><plain>The SAP was approved and signed off by the study Steering Committee in May 2015. </plain></SENT>
<SENT sid="43" pm="."><plain>Participant recruitment to the alteplase dose arm was completed in August 2015, and final patient follow‐up occurred in November 2015. </plain></SENT>
<SENT sid="44" pm="."><plain>The statistical analyses specified in the SAP occurred in January 2016, and the main results announced at the European Stroke Organisation conference in Barcelona in May 2016. </plain></SENT>
</text></p><p><text><SENT sid="45" pm="."><plain>Critical appraisal of the noninferiority results of ENCHANTED should follow the principles and criteria used in assessing any study of novel management strategies 18. </plain></SENT>
<SENT sid="46" pm="."><plain>Special attention will need to be given to assessing the results of both the as‐randomized, intent‐to‐treat, and per‐protocol population analyses, and of any trade‐offs that may arise between the potential benefits (lower risk of sICH) and harms (loss of efficacy in AIS due to large vessel occlusion) of low‐dose compared with standard‐dose alteplase. </plain></SENT>
<SENT sid="47" pm="."><plain>If the proposed estimates of noninferiority boundary for low‐dose alteplase hold, the results of ENCHANTED could translate into improved effectiveness, safety, and accessibility of thrombolytic treatment for many AIS patients around the world. </plain></SENT>
</text></p><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="48" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data"><caption><p><text><SENT sid="49" pm="."><plain>Appendix S1. Statistical analysis plan. </plain></SENT>
</text></p></caption><media xlink:href="IJS-10-1313-s001.docx"><caption><p><text><SENT sid="50" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack id="ijs12602-sec-0007"><title>Acknowledgements</title><p><text4fund><text><SENT sid="51" pm="."><plain>We sincerely thank the ENCHANTED investigators, coordinators, and project staff for their hard work and dedication to the study. </plain></SENT>
<SENT sid="52" pm="."><plain>We also thank the patients and their families for participating in this study, and the ENCHANTED Steering Committee and expert Advisory Committee listed in Reference 16 who commented on this report. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list id="ijs12602-bibl-0001"><title>References</title><ref id="ijs12602-bib-0001"><text><SENT sid="53" pm="."><plain>1 The National Institute of Disorders and Stroke rt‐PA Stroke Study group. </plain></SENT>
<SENT sid="54" pm="."><plain>Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581–1587.7477192 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0002"><text><SENT sid="55" pm="."><plain>2  Emberson J ,  Lees KR ,  Lyden P  et al Effect of treatment delay, age and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta‐analysis of individual patient data from randomised trials. Lancet 2014; 384:1929–1935.25106063 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0003"><text><SENT sid="56" pm="."><plain>3  Wardlaw JM ,  Murray V ,  Berge E  et al Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta‐analysis. Lancet 2012; 379:2364–2372.22632907 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0004"><text><SENT sid="57" pm="."><plain>4  Brott TG ,  Haley EC Jr ,  Levy DE  et al Urgent therapy for stroke. </plain></SENT>
<SENT sid="58" pm="."><plain>Part I. </plain></SENT>
<SENT sid="59" pm="."><plain>Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632–640.1579958 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0005"><text><SENT sid="60" pm="."><plain>5  Haley EC Jr ,  Levy DE ,  Brott TG  et al Urgent therapy for stroke. </plain></SENT>
<SENT sid="61" pm="."><plain>Part II. </plain></SENT>
<SENT sid="62" pm="."><plain>Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 1992; 23:641–645.1579959 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0006"><text><SENT sid="63" pm="."><plain>6  Haley EC Jr ,  Brott TG ,  Sheppard GL  et al Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke: the TPA Bridging Study Group. Stroke 1993; 24:1000–1004.8322373 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0007"><text><SENT sid="64" pm="."><plain>7  Mori E ,  Yoneda Y ,  Tabuchi M  et al Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976–982.1579252 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0008"><text><SENT sid="65" pm="."><plain>8  Yamaguchi T ,  Kikuchi H ,  Hayakawa H . Clinical efficacy and safety of intravenous tissue plasminogen activator in acute ischaemic stroke; in YamaguchiT, MoriE, MinematsuK, del ZoppoGJ (eds): Thrombolytic Therapy in Acute Ischaemic Stroke III. Tokyo, Springer‐Verlag, 1995:223–229. </plain></SENT>
</text></ref><ref id="ijs12602-bib-0009"><text><SENT sid="66" pm="."><plain>9  Yamaguchi T ,  Mori E ,  Minematsu K  et al Alteplase at 0·6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J‐ACT). Stroke 2006; 37:1810–1815.16763187 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0010"><text><SENT sid="67" pm="."><plain>10  Sharma VK ,  Ng KW ,  Venketasubramanian N  et al Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke 2011; 6:523–530.22111797 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0011"><text><SENT sid="68" pm="."><plain>11  Pandian JD ,  Srikanth V ,  Read SJ ,  Thrift AG . Poverty and stroke in India: a time to act. Stroke 2007; 38:3063–3069.17954905 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0012"><text><SENT sid="69" pm="."><plain>12  Tsai CF ,  Thomas B ,  Sudlow CLM . Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 2013; 81:264–272.23858408 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0013"><text><SENT sid="70" pm="."><plain>13  Menon BK ,  Saver JL ,  Prabhakaran S  et al Risk score for intracranial haemorrhage in patients with acute ischemic stroke treated with intravenous tissue‐type plasminogen activator. Stroke 2012; 43:2293–2299.22811458 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0014"><text><SENT sid="71" pm="."><plain>14  Wardlaw JM ,  Koumellis P ,  Liu M . Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev 2013; (5):Art. </plain></SENT>
<SENT sid="72" pm="."><plain>No.: <ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="CD000514">CD000514</ext-link>. doi: <ext-link ext-link-type="doi" xlink:href="10.1002/14651858.CD000514.pub">10.1002/14651858.CD000514.pub</ext-link>. </plain></SENT>
</text></ref><ref id="ijs12602-bib-0015"><text><SENT sid="73" pm="."><plain>15  Anderson CS ,  Huang Y ,  Wang JG  et al Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008; 7:391–399.18396107 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0016"><text><SENT sid="74" pm="."><plain>16  Huang Y ,  Sharma VK ,  Robinson T  et al Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: an international multicenter 2 × 2 quasi‐factorial randomized controlled trial of low‐ vs. standard‐dose rt‐PA and early intensive vs. guideline‐recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment. Int J Stroke 2015; 10:778–788.25832995 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0017"><text><SENT sid="75" pm="."><plain>17  Anderson CS ,  Heeley E ,  Huang Y  et al Rapid blood pressure lowering in acute intracerebral hemorrhage. N Engl J Med 2013; 368:2355–2365.23713578 </plain></SENT>
</text></ref><ref id="ijs12602-bib-0018"><text><SENT sid="76" pm="."><plain>18  Mulla SM ,  Scott IA ,  Jackevicius CA ,  You JJ ,  Guyatt GH . How to use a noninferiority trial: users' guides to the medical literature. JAMA 2012; 308:2605–2611.23268519 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
